Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
How often do you monitor pulmonary function tests in patients with fibrotic lung disease?
Answer from: at Academic Institution
For IPF patients and those on IS meds, every 4 months, I obtain Spirometry and DLCO. I obtain six-minute walk tests every 4-6 months.
Comments
at Medical Center Pulmonary Consultants
3-6 months.
13806
Sign in or Register to read more
25137
Related Questions
Do you consider administration of nintedanib or pirfenidone via enteral tube in patients unable to take PO due to recurrent aspiration?
What immunosuppression regimens do clinicians use in patients with progressive RB-ILD despite smoking cessation and prednisone?
What is your approach to evaluating amiodarone induced interstitial pneumonitis?
What is the duration of steroids that you prescribe for organizing pneumonia?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
How do you determine whether to add abatacept or rituximab to the treatment regimen in patients with mild RA-ILD on methotrexate?
What is your approach to evaluation and management of GERD in a patient with IPF?
Do you monitor CBCs to assess for drug toxicity in patients on nintedanib?
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
What factors would encourage you to choose abatacept vs tocilizumab in a patient with RA-ILD with a UIP pattern of pulmonary fibrosis?
3-6 months.